Sarcopenia in the setting of nonalcoholic fatty liver

Keyphrases

• Asian Population 8%
• Biochemical Pathways 8%
• Blood Cortisol 8%
• Carbohydrates 8%
• Cause-effect 8%
• Cellular Level 8%
• Cortisol 50%
• Cushing's Syndrome 8%
• Disease Pathophysiology 8%
• Disorder Effects 8%
• Elevated Concentrations 8%
• FDA-approved Drugs 8%
• Health Problems 8%
• Hydroxysteroid Dehydrogenase 8%
• Insulin Resistance 8%
• Intracellular Activity 8%
• Liver Problems 8%
• Metabolic Syndrome 8%
• Metabolism 16%
• Muscle Loss 8%
• Muscle-liver Axis 8%
• Non-alcoholic Fatty Liver Disease (NAFLD) 100%
• Obesity 8%
• Pathologic Conditions 8%
• Potential Biomarkers 8%
• Related Disorders 8%
• Sarcopenia 100%
• Steroid Precursors 8%

Medicine and Dentistry

• Biological Marker 8%
• Cushing Syndrome 8%
• Cytokine 8%
• Disease 33%
• Glucocorticoid 8%
• Hydrocortisone 58%
• Hydroxysteroid Dehydrogenase 8%
• Insulin Resistance 8%
• Metabolic Syndrome 8%
• Nonalcoholic Fatty Liver 100%
• Pathophysiology 8%
• Precursor 8%
• Prevalence 8%
• Sarcopenia 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Biological Marker 8%
• Cushing Syndrome 8%
• Cytokine 8%
• Disease 33%
• Glucocorticoid 8%
• Hydrocortisone 58%
• Hydroxysteroid Dehydrogenase 8%
• Insulin Resistance 8%
• Metabolic Syndrome X 8%
• Nonalcoholic Fatty Liver 100%
• Pathophysiology 8%
• Prevalence 8%
• Sarcopenia 100%